PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportshyperkalemia
MeSH D006947 - hyperkalemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D014883:Water-electrolyte imbalance
1 Company
1 Drug
$
Success rate
D006947: 
Hyperkalemia
2 Companies
2 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
AstraZenecaSodium zirconium cyclosilicate Lokelma 2032-02-10 2018-05-18 $233 M Q2/21-Q2/24 
ViforPatiromer Veltassa  2017-07-19   
Clinical Trials
Historical Success Rate
Phase 1
25%
1/4
Phase 2
78%
7/9
Phase 3
58%
7/12
Approved: 5Overall Success rate: 11%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
AstraZeneca
Sodium zirconium cyclosilicate,
Angiotensin ii,
Benzocaine,
Ademetionine,
Aldosterone,
Aspartame,
Bevifimod,
Sodium polystyrene sulfonate,
Spirolactone,
Viaject,
Lcz696,
Bolus,
Kcl
Vifor
Patiromer,
Txa127,
Sodium lactate,
Aldosterone,
Aspartame,
Corticorelin,
Microcrystalline cellulose,
Spirolactone,
Kcl
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use